Treatment After Exposure to HIV
August 13, 2013
What Is Post-Exposure Prophylaxis?
Prophylaxis means disease prevention. Post-exposure prophylaxis (or PEP) means taking antiretroviral medications (ARVs) as soon as possible after exposure to HIV, so that the exposure will not result in HIV infection. These medications are only available with a prescription. PEP should begin as soon as possible after exposure to HIV, but certainly within 72 hours. Treatment with 2 or 3 ARVs should continue for 4 weeks, if tolerated.
Researchers are also developing Pre-exposure Prophylaxis (PrEP). PrEP might be used in similar ways as a vaccine. Fact Sheet 160 has more information on PrEP.
Who Should Use PEP?
PEP has been standard procedure since 1996 for healthcare workers exposed to HIV. Workers start taking medications within a few hours of exposure. Usually the exposure is from a "needle stick," when a health care worker accidentally gets jabbed with a needle containing HIV-infected blood. PEP reduced the rate of HIV infection from workplace exposures by 79%. However, it is still possible for health care workers who take PEP to get HIV infection.
In 2005, the Centers for Disease Control reviewed information on PEP. They concluded that it should also be available for use after HIV exposures that are not work-related. People can be exposed to HIV during unsafe sexual activity, when a condom breaks during sex, or if they share needles for injecting drugs. Infants can be exposed if they drink breast milk from an infected woman. In a study of PEP in 400 cases of possible sexual exposure to HIV, not one person became infected with HIV.
Should PEP Be Used for Non-Occupational Exposure?
HIV exposure at work is usually a one-time accident. Other HIV exposures may be due to unsafe behaviors that can occur many times. Some people think that PEP might encourage this unsafe behavior if people think that PEP is an easy way to avoid HIV infection.
There are other reasons why PEP might not be a good idea for non-occupational exposure:
Despite these concerns, there is growing interest in PEP for non-occupational exposure. Most programs include counseling to inform and encourage people to avoid exposure to HIV.
How Is PEP Taken?
PEP should be started as soon as possible after exposure to HIV.
The US Public Health Service recommends using a combination of three approved ARVs for four weeks. Previous guidelines were based on how serious the HIV exposure was. This has been eliminated in the guidelines issued in 2013. It is now recommended that all exposures are treated the same way. In January 2001, the Centers for Disease Control warned against using nevirapine (Viramune) for PEP because of the risk of liver damage. See Fact Sheet 431 for more information on nevirapine. The CDC has updated its PEP recommendations in August of 2013. They are on the Internet at www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm.
What Are the Side Effects?
The most common side effects from PEP medications are nausea and generally not feeling well. Other possible side effects include headaches, fatigue, vomiting and diarrhea. For more information, see the fact sheets on individual ARVs.
The Bottom Line
Post-exposure prophylaxis (PEP) is the use of ARVs as soon as possible after exposure to HIV, to prevent HIV infection. PEP can reduce the rate of infection in health care workers exposed to HIV by 79%.
The benefits of PEP for non-occupational exposure have not been proven. This use of PEP is controversial because some people fear it will encourage unsafe behaviors.
PEP is a four-week program of two or three ARVs, several times a day. The medications have serious side effects that can make it difficult to finish the program. PEP is not 100% effective; it cannot guarantee that exposure to HIV will not become a case of HIV infection.
For More Information
CDC guidelines on PEP are on the Internet.
The CDC recently issued guidelines on pre-exposure prophylaxis (PrEP): www.cdc.gov/hiv/prep/
This article was provided by AIDS InfoNet. Visit AIDS InfoNet's website to find out more about their activities and publications.